Precision BioSciences, Inc.
$7.58
▲
2.28%
2026-04-21 06:30:01
precisionbiosciences.com
NCM: DTIL
Explore Precision BioSciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$187.43 M
Current Price
$7.58
52W High / Low
$8.82 / $3.53
Stock P/E
—
Book Value
$3.83
Dividend Yield
—
ROCE
-35.84%
ROE
-62.71%
Face Value
—
EPS
$-3.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
68
Beta
1.09
Debt / Equity
31.23
Current Ratio
13.32
Quick Ratio
13.32
Forward P/E
-1.96
Price / Sales
5.02
Enterprise Value
$78.15 M
EV / EBITDA
-1.54
EV / Revenue
2.28
Rating
None
Target Price
$32
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 2. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 3. | Relmada Therapeutics, Inc. | $7.37 | — | $773.03 M | — | -67.49% | -25.62% | $7.94 / $0.27 | $1.18 |
| 4. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 5. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 6. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 7. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 34.2 M | 0.01 M | 0.02 M | 0.03 M | 0.64 M | — |
| Operating Profit | 12.51 M | -20.67 M | -21.88 M | -22.11 M | -24.85 M | — |
| Net Profit | 20.13 M | -21.77 M | -23.52 M | -20.57 M | -17.75 M | — |
| EPS in Rs | 0.78 | -0.84 | -0.91 | -0.8 | -0.69 | -2.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 34.26 M | 68.7 M | 48.73 M | 25.1 M |
| Operating Profit | -52.15 M | -26.16 M | -43.74 M | -62.31 M |
| Net Profit | -45.72 M | 7.17 M | -61.32 M | -111.64 M |
| EPS in Rs | -1.77 | 0.28 | -2.38 | -4.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 154.42 M | 136.39 M | 159.78 M | 238.17 M |
| Total Liabilities | 62.17 M | 80 M | 140.92 M | 177.74 M |
| Equity | 92.25 M | 56.39 M | 18.86 M | 60.43 M |
| Current Assets | 118.74 M | 94.99 M | 136.36 M | 199.1 M |
| Current Liabilities | 8.91 M | 14.98 M | 49.99 M | 59.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -65.84 M | -58.45 M | -84.11 M | -45.75 M |
| Investing CF | -0.63 M | -0.21 M | 5.83 M | -3.32 M |
| Financing CF | 95.16 M | 50.45 M | 5.39 M | 94.98 M |
| Free CF | -66.54 M | -58.72 M | -86.39 M | -49.07 M |
| Capex | -0.7 M | -0.28 M | -2.28 M | -3.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 40.98% | 94.15% | — | — |
| Earnings Growth % | 111.69% | 45.07% | — | — |
| Profit Margin % | 10.43% | -125.84% | -444.8% | — |
| Operating Margin % | -38.08% | -89.76% | -248.26% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 19.69% | -65.76% | -250.2% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-02-14 | 1:0.0333333 |